We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Aclara Resources Inc | TSX:ARA | Toronto | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.54 | 0.54 | 0.56 | 0 | 14:57:13 |
"The Optix MX3 addresses a real market need as customers in the drug discovery and development process continue to demand tools providing an extensive qualitative and quantitative data set in small animal research, while ensuring reliability and performance for applications requiring longitudinal studies," said Sebastien Gignac, Chairman & CEO of ART. "While products currently on the market can only detect the intensity of the signal coming from a mouse specimen, the Optix MX3 system quite effectively exploits the power of our time domain technology to move beyond this type of signal measurement to obtain much richer and complex data. Indeed, with our Optix MX3, scientists are actually able to gain confidence in the exactitude of their results, by accurately differentiating various compound types and determining their concentration and depth precisely."
"We are excited to announce that the Optix MX3 is now available through our dedicated sales teams in North America and Europe, as well as our regional distribution partners in Italy, India, Japan, Korea and the United Kingdom," said Dino DiCamillo, Vice President, Global Sales & Marketing, of ART.
The compact Optix MX3 system offers the highest sensitivity among fluorescent systems in the preclinical market and unique optical molecular imaging features. The completely re-engineered and redesigned Optix platform will mean an increase in performance level, entail savings in manufacturing costs, and will incorporate new technological market drivers, such as the ability to image red fluorescent proteins, Q-dots, and the complete spectrum ranging from 450 nm to 850 nm with the support of a state-of-the-art tunable laser.
Using ART's proven and proprietary time-domain technology, which allows measurement of the light's time of arrival, Optix MX3 is sensitive enough to detect target signals deep within the organs of small animals. Unique to the Optix MX3 is the ability to recover fluorescence lifetime, which can be used to separate and quantify fluorescent probe distributions depending on their respective biochemical environment. Also part of the Optix MX3 is the CT fusion software package allowing researchers to export the scan obtained using Optix MX3 in DICOM format, and fuse it with micro-CT for a full 3D anatomical reference.
About ART
ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. Finally, the Fenestra® line of molecular imaging contrast products provides image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. ART is commercializing some of these products in a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. ART's shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit our website at www.art.ca.
This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in the most recent Annual Information Form and the financial statements for the year ended December 31, 2008, available on SEDAR (www.sedar.com).
Contacts: ART Advanced Research Technologies Inc. Dino DiCamillo Vice President, Global Sales and Marketing, Preclinical Imaging ddicamil@art.ca ART Advanced Research Technologies Inc. Jacques Bedard Chief Financial Officer 514-832-0777 jbedard@art.ca www.art.ca
1 Year Aclara Resources Chart |
1 Month Aclara Resources Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions